Analysts predict that Codexis, Inc. (NASDAQ:CDXS) will report earnings of $0.06 per share for the current quarter, Zacks reports. Three analysts have provided estimates for Codexis’ earnings, with the lowest EPS estimate coming in at $0.03 and the highest estimate coming in at $0.10. Codexis reported earnings of ($0.13) per share during the same quarter last year, which suggests a positive year over year growth rate of 146.2%. The firm is scheduled to report its next earnings report on Thursday, March 8th.

On average, analysts expect that Codexis will report full year earnings of ($0.46) per share for the current fiscal year, with EPS estimates ranging from ($0.48) to ($0.43). For the next financial year, analysts forecast that the business will post earnings of ($0.14) per share, with EPS estimates ranging from ($0.31) to ($0.01). Zacks’ earnings per share calculations are an average based on a survey of research firms that that provide coverage for Codexis.

Several equities analysts have commented on the stock. BidaskClub raised shares of Codexis from a “hold” rating to a “buy” rating in a research report on Friday. HC Wainwright reissued a “buy” rating and issued a $8.50 price target on shares of Codexis in a research report on Tuesday, November 21st. Jefferies Group raised their price target on shares of Codexis from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Friday, October 13th. Zacks Investment Research raised shares of Codexis from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, ValuEngine raised shares of Codexis from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $7.50.

Institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN raised its holdings in shares of Codexis by 103.2% in the 2nd quarter. Wells Fargo & Company MN now owns 119,294 shares of the biotechnology company’s stock valued at $650,000 after purchasing an additional 60,600 shares in the last quarter. Telemark Asset Management LLC acquired a new stake in shares of Codexis in the 3rd quarter valued at $13,633,000. William Blair Investment Management LLC raised its holdings in shares of Codexis by 10.5% in the 2nd quarter. William Blair Investment Management LLC now owns 1,090,072 shares of the biotechnology company’s stock valued at $5,941,000 after purchasing an additional 103,233 shares in the last quarter. Baillie Gifford & Co. raised its holdings in shares of Codexis by 1.1% in the 3rd quarter. Baillie Gifford & Co. now owns 1,478,097 shares of the biotechnology company’s stock valued at $9,830,000 after purchasing an additional 16,684 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Codexis by 28.8% in the 2nd quarter. Northern Trust Corp now owns 453,656 shares of the biotechnology company’s stock valued at $2,473,000 after purchasing an additional 101,432 shares in the last quarter. Institutional investors and hedge funds own 65.71% of the company’s stock.

Shares of Codexis (NASDAQ:CDXS) traded up $0.15 during mid-day trading on Monday, reaching $7.70. 300,009 shares of the company’s stock traded hands, compared to its average volume of 233,598. Codexis has a 52 week low of $3.60 and a 52 week high of $7.95.

ILLEGAL ACTIVITY NOTICE: “$0.06 EPS Expected for Codexis, Inc. (CDXS) This Quarter” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/17/0-06-eps-expected-for-codexis-inc-cdxs-this-quarter.html.

Codexis Company Profile

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Get a free copy of the Zacks research report on Codexis (CDXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Codexis (NASDAQ:CDXS)

Receive News & Stock Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related stocks with our FREE daily email newsletter.